Fewer than one in 10 individuals that would benefit from obesity jabs like Wegovy are able to get them, warns the World Health Organization as it releases its first guidance on the drugs.
With in excess of 1,000,000,000 individuals worldwide now classified as obese, it is advocating for broader and more equitable access to this class of drugs.
According to estimates, over two billion will be obese by 2030 without intervention.
"The latest guidelines acknowledges that obesity is a lifelong illness that can be addressed with thorough and lifelong care," stated the agency's head Tedros Adhanom Ghebreyesus.
Significant expense, constrained manufacturing, and distribution challenges are key hurdles to widespread availability to the injections that can help people shift substantial body mass, notes the agency.
Skinny Jab Shortage
Even in the current best projected outlook, the manufacturing of these medications could only cover about 100 million people – less than 10% of eligible patients, per the WHO.
The advice urges governments and firms to increase availability, through approaches including licensing agreements.
Exclusive production rights on semaglutide – the primary ingredient of a leading brand – is set to lapse in several countries in 2026.
How Weight-Loss Injections Function
The injections imitate a biological compound to slow digestion, suppress the appetite and increase satiety so individuals reduce food intake.
Individuals usually see weight reduction within a few weeks of starting on the regular doses.
Studies indicates people may see weight return after a year of halting the drug, as their normal food cravings come back.
To be overweight or obese elevates your risk for experiencing medical conditions, including type 2 diabetes, heart disease, brain attack, and certain cancers.
Excess weight concerns individuals in every country and was linked to 3.7 million fatalities worldwide in 2024, according to the WHO.
